| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.5 | 4e-23 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.21 | 1e-05 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | 0.18 | 5e-05 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.19 | 0.0002 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.18 | 0.0002 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.16 | 0.002 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.15 | 0.003 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.12 | 0.009 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.11 | 0.03 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.1 | 0.05 |